Yep, saftey, complete responses, billion dollar market, path to registrational trial, MAST and OASIS trial updates coming. All really great, but already known and priced in prior to this latest announcement.
If Imugene was undervalued last week, there is no reason it would be any less undervalued this week.
They added another 3 CRs to the 39 previous CRs, said it's still safe and that they're slightly behind schedule due to tweaking the treatment regime. Nothing to trigger a re-rate.
I do reckon the SP may start to climb sometime between now and the AGM, as they will likely make sure that both the MAST amd OASIS trial updates are out before then, and investors/traders will anticipate that.
I really hope they don't entertain any TO/trade sale offers any time soon. It's clear that many investors have poor sentiment at the moment and would likely vote through a cheap offer. Not sure we're at the point of attracting a bidding war yet either. As I've said before, I'm here for $$ not cents, need to be patient.
.
IMU Price at posting:
5.8¢ Sentiment: Buy Disclosure: Held
(20min delay)